

- Powell RG, Weisleder D, Smith CR, et al. Antitumor alkaloids from *Cephalotaxus harringtonia* structure and activity. *J Pharm Sci* 1972;61:1227–1230.
- Huang MT. Harringtonine, an inhibitor of initiation of protein biosynthesis. *Mol Pharmacol* 1975;11:511–519.
- Baaske DM, Heinstejn P. Cytotoxicity and cell cycle specificity of homoharringtonine. *Antimicrob Agents Chemother* 1977;12:298–300.
- Savaraj N, Lu K, Dimery I, et al. Clinical pharmacology of homoharringtonine. *Cancer Treat Rep* 1986;70:1403–1407.
- Neidhart JA, Young DC, Derocher D, et al. Phase I trial of homoharringtonine. *Cancer Treat Rep* 1983;67:801–804.
- Grem JL, Cheson BD, King SA, et al. Cephalotaxine esters: antileukemic advance of therapeutic failure. *J Natl Cancer Inst* 1988;80:1095–1103.
- O'Brien S, Kantarjian H, Keating M, et al. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. *Blood* 1995;86:3322–3326.
- Legros L, Hayette S, Nicolini FE, et al. BCR-ABL(T3151) transcript disappearance in an imatinib-resistant CML patient treated with homoharringtonine: a new therapeutic challenge? *Leukemia* 2007;21(10):2204–2206.
- Jorge Cortes J, Lipton JF, Rea D, et al. Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T3151 mutation. *Blood* 2012;120:2573–2580.
- Labrou NE, Papageorgiou AC, Avramis VI. Structure-function relationships and clinical applications of L-Asparaginases. *Curr Med Chem* 2010;17:2183–2195.
- Verma N, Kumar K, Kaur G, et al. L-Asparaginase: a promising chemotherapeutic agent. *Crit Rev Biotechnol* 2007;27:45–62.
- Zeidan A, Wang ES, Wetzler M. Pegasparaginase: where do we stand? *Expert Opin Biol Ther* 2009;9:111–119.
- Avramis VI, Panosyan EH. Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future. *Clin Pharmacokinet* 2005;44:367–393.
- Appel IM, Hop WC, Pieters R. Changes in hypercoagulability by asparaginase: a randomized study between two asparaginases. *Blood Coagul Fibrinolysis* 2006;17:139–146.
- Evans WE, Yee GC, Crom WR, et al. Clinical pharmacology of bleomycin and cisplatin. *Head Neck Surg* 1981;4:98–110.
- Chen J, Stubbe J. Bleomycins: towards better therapeutics. *Nat Rev Cancer* 2005;2:102–112.
- Hecht SM. Bleomycin: new perspectives on the mechanism of action. *J Nat Prod* 2000;63:158–168.
- Lewis TG, Nydorf ED. Intralesional bleomycin for warts: a review. *J Drugs Dermatol* 2006;5:499–504.
- Shaw P, Agarwal R. Pleurodesis for malignant pleural effusions. *Cochrane Database Syst Rev* 2004;(1):CD002916.
- Good LM, Miller MD, High WA. Intralesional agents in the management of cutaneous malignancy: a review. *J Am Acad Dermatol* 2011;64:413–422.
- Kawai K, Akaza H. Bleomycin-induced pulmonary toxicity in chemotherapy for testicular cancer. *Expert Opin Drug Saf* 2003;2:587–596.
- Azulay E, Herigault S, Levame M, et al. Effect of granulocyte colony-stimulating factor on bleomycin-induced acute lung injury and pulmonary fibrosis. *Crit Care Med* 2003;31:1442–1448.
- Adachi K, Suzuki M, Sugimoto T, et al. Effects of granulocyte colony-stimulating factor on the kinetics of inflammatory cells in the peripheral blood and pulmonary lesions during the development of bleomycin-induced lung injury in rats. *Exp Toxicol Pathol* 2003;55:21–32.
- Martin WG, Ristow KM, Habermann TM, et al. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. *J Clin Oncol* 2005;23:7614–7620.
- Younes A, Connors JM, Park SI et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase I, open-label, dose-escalation study. *Lancet Oncol* 2013;14:1348–1356.
- Lam MS. The need for routine bleomycin test dosing in the 21st century. *Ann Pharmacother* 2005;39:1897–1902.
- Swaffar DS, Horstman MG, Jaw JY, et al. Methylazoxypocarbazine, the active metabolite responsible for the anticancer activity of procarbazine against L1210 leukemia. *Cancer Res* 1989;49:2442–2447.
- Patterson LH, Murray GI. Tumour cytochrome P450 and drug activation. *Curr Pharm Des* 2002;8:1335–1347.
- Swaffar DS, Pomerantz SC, Harker WG, et al. Non-enzymatic activation of procarbazine to active cytotoxic species. *Oncol Res* 1992;4:49–58.
- Preiss R, Baumann F, Regenthal R, et al. Plasma kinetics of procarbazine and azo-procarbazine in humans. *Anticancer Drugs* 2006;17:75–80.
- Von Hoff DD, LoRusso PM, Rudin CM, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. *N Engl J Med* 2009;361:1164–1172.
- Rudin CM. Vismodegib. *Clin Cancer Res* 2012;18:1–5.
- U.S. Food and Drug Administration. News & Events: FDA News Release: FDA approves new treatment for most common types of skin cancer. <http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm289545.htm>. Published January 30, 2012. Updated January 31, 2012.
- Tang JY, Mackay-Wiggan JM, Aszterbaum M, et al. Inhibiting the Hedgehog pathway in patients with the basal-cell nevus syndrome. *N Engl J Med* 2012;366:2180–2188.
- Krop IE, Beeram M, Modi S, et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. *J Clin Oncol* 2010;28:2698–2704.
- Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. *N Engl J Med* 2012;367:1783–1791.
- Sehgal SN, Baker H, Vézina C. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. *J Antibiot (Tokyo)* 1975;28:727–732.
- Sehgal SN, Molnar-Kimber K, Ocain TD, et al. Rapamycin: a novel immunosuppressive macrolide. *Med Res Rev* 1994;14:1–22.
- Wullschlegel S, Loewith R, Hall MN. TOR signaling in growth and metabolism. *Cell* 2006;124:471–484.
- Raymond E, Alexandre J, Faivre S, et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor in patients with cancer. *J Clin Oncol* 2004;22:2336–2347.
- Zeng Z, Sarbassov dos D, Samudio JJ, et al. Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. *Blood* 2007;109:3509–3512.
- Kapoor A, Figlin RA. Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma. *Cancer* 2009;115:3618–3630.
- Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. *J Clin Oncol* 2004;22:909–918.
- Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. *N Engl J Med* 2007;356:2271–2281.
- Smith SM, van Besien K, Karrison T, et al. Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium. *J Clin Oncol* 2010;28:4740–4746.
- Duran I, Siu LL, Oza AM, et al. Characterization of the lung toxicity of the cell cycle inhibitor temsirolimus. *Eur J Cancer* 2006;42:1875–1880.
- Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. *Transplantation* 1997;64:36–42.
- Dudkin L, Dilling MB, Cheshire PJ, et al. Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. *Clin Cancer Res* 2001;7:1758–1764.
- Kirchner GL, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. *Clin Pharmacokinet* 2004;43:83–95.
- Doi T, Muro K, Boku N, et al. Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. *J Clin Oncol* 2010;28:1904–1910.
- Yao JC, Lombard-Bohas C, Baudin E, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. *J Clin Oncol* 2010;28:69–76.
- Yee KW, Zeng Z, Konopleva M, et al. Phase III study of the mammalian target of rapamycin inhibitor everolimus(RAD001) in patients with relapsed or refractory hematological malignancies. *Clin Cancer Res* 2008;12:5165–5173.
- Okuno S. Mammalian target of rapamycin inhibitors in sarcomas. *Curr Opin Oncol* 2006;18:360–362.
- Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. *N Engl J Med* 2011;364:514–523.
- Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. *N Engl J Med* 2012;366:520–529.
- Shortt J, Hsu AK, Johnstone RW. Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy. *Oncogene* 2013;32:4191–4202.
- Zhu YX, Kortuem KM, Stewart AK. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. *Leuk Lymphoma* 2013;54:683–687.
- Escoubet-Lozach L, Lin IL, Jensen-Pergakes K, et al. Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. *Cancer Res* 2009;69:7347–7356.
- Madan S, Lacy MQ, Dispenzieri A, et al. Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma. *Blood* 2011;118:1763–1765.
- Lacy MQ, Tefferi A. Pomalidomide therapy for multiple myeloma and myelofibrosis: an update. *Leuk Lymphoma* 2011;52:560–566.
- Ito T, Ando H, Suzuki T, et al. Identification of a primary target of thalidomide teratogenicity. *Science* 2010;327:1345–1350.
- Zhu YX, Braggio E, Shi CX, et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. *Blood* 2011;118:4771–4779.

63. Lopez-Girona A, Mendy D, Ito T, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. *Leukemia* 2012;26:2326–2335.
64. Schuster SR, Kortuem KM, Zhu YX, et al. Cereblon expression predicts response, progression free and overall survival after pomalidomide and dexamethasone therapy in multiple myeloma. *ASH Ann Meeting Abstracts* 2012;120:194.
65. Bennett CL, Angelotta C, Yarnold PR, et al. Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. *JAMA* #2006;296:2558–2560.
66. Rao KV. Lenalidomide in the treatment of multiple myeloma. *Am J Health Syst Pharm* 2007;64:1799–1807.
67. Lenalidomide. Drugs@FDA. Food and Drug Administration Web site. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021880s006s016s0171bl.pdf. Published December 2008.
68. Pomalidomide. Drugs@FDA. Food and Drug Administration Web site. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/2040261bl.pdf. Revised February 2013.
69. Lacy MQ, McCurdy AR. Pomalidomide. *Blood* 2013;122:2305–2309.